Clin2
NCT07583641Possibly a fitRecruiting

Testing Efgartigimod for Autoimmune Brain Inflammation

Autoimmune Encephalitis (AE)

Part of Brain & nervous system, Immune system & allergy clinical trials.

This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
170 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • You are at least 12 years old
  • You have been diagnosed with possible or confirmed autoimmune encephalitis (AIE)
  • You have not received certain blood-filtering treatments (PLEX) or immune infusions (Ig) for AIE in the past, or not in the last 3 months for other conditions (Part A only)
  • You do not test positive for anti-MOG antibodies
  • You have no major surgery planned during the study, except for AIE-related brain or chest tumors
  • No active substance abuse or untreated psychiatric conditions unrelated to your AIE

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07707739Recruiting
Plasma exchange for children with autoimmune encephalitis

This trial tests whether plasma exchange (a procedure that cleans the blood) can help children with a severe form of autoimmune encephalitis—a condition where the immune system attacks the brain. It's for children who haven't gotten better with standard treatments like steroids or IVIG.

Shibīn al Kawm, Menoufia Governorate
NCT07488117Recruiting· Phase 2
PET scan to detect brain inflammation in autoimmune encephalitis

This trial uses a special PET scan (with a tracer called [18F]-DPA-714) to see if it can measure inflammation in the brain caused by autoimmune encephalitis. The goal is to see if this scan can help doctors diagnose and monitor the condition more accurately.

Toulouse
NCT05979441Enrolling by invitation· Phase 3
Long-term safety of efgartigimod injection for myositis

This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.

Phoenix, Arizona
NCT05374590Enrolling by invitation· Phase 2/Phase 3
Long-term safety study of efgartigimod for young myasthenia gravis patients

This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.

Chicago, Illinois
NCT06392386Recruiting· Phase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis

This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.

Charlotte, North Carolina
NCT06760091Not yet recruiting
Autoimmune encephalitis study

This study is for people with autoimmune encephalitis, a condition where the immune system attacks the brain. It aims to collect information about this disease to learn more about it and how to treat it.

Beijing

Hear when a new Autoimmune Encephalitis (AE) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.